The Israeli company Cannabotech has imagined combining mushrooms with cannabis. A dream for some, but in reality a desire to meet medical needs.
The company is working on a range of products that not only combine the compounds found in mushrooms with those of cannabis, but also modify the proportions in which they are naturally present to increase their effectiveness.
"We believe that in a few years, there will be no difference between cannabis growers and others who grow food," says Elchananan Shaked, co-founder and CEO of Cannabotech.
"Each cannabis plant contains 30 40 active cannabinoids and several hundred cannabinoids in total. We believe that the secret of the plant's activity lies in the cannabinoids that appear in small amounts in the plant. If you change the relationship between them and increase their concentration in the final product, you will get very high medical efficacy and unique compounds for the treatment of various diseases, "says Shaked.
To date, the company has developed five of these products for the treatment of colon cancer, infertility, liver overload of lipids, reduction of inflammation and heart and vascular diseases.
These products are awaiting clinical trials. Many patients who consume cannabis swear by the virtues of the plant in its natural state. For Shaked, it will be necessary to convince these consumers: "We will use science to show them. We believe that the entire industry is moving in this direction. Today, only 1% of the population consumes cannabis. We believe that much larger population groups will consume special compounds that are scientifically validated for specific diseases. "
The compounds are developed with the help of Professor Fuad Fares, one of the inventors of the technology used by Prolor Biotech, who has developed a delayed release technology for protein-based drugs.
This technology allows you to inject drugs at intervals of a week or more, rather than daily. Several companies are considering developing cannabis compounds in which the ratio of active compounds in the plant is changed.
The special feature of Cannabotech is the inclusion of mushrooms. "Penicillin comes from fungi, just like chemotherapy," says Shaked. "The benefits of mushrooms have been researched for thousands of years. Professor Solomon Wasser has been researching fungi at Haifa University for decades. He has huge reserves of mushroom compounds and has compiled information collected over the years about the treatments that use them and their interactions with other ingredients. "
Another feature that distinguishes Cannabotech from other cannabis research companies for medical purposes is the fact that it intends to obtain its investment through crowdfunding, rather than relying on private investors. "We believe we need to build the business from below, with no guidance from financial market specialists," said Shaked. "I believe in obtaining capital from the public. "
So far, it seems that Cannabotech is looking to stick to non-psychedelic mushrooms for its cannabis blends, but more and more research shows that psilocybin can be as effective a drug as medical marijuana.